MSLE PE Ratio & Valuation, Is MSLE Overvalued

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MSLE competitors is 11.96, providing a benchmark for relative valuation. Satellos Bioscience Inc Corp (MSLE.O) exhibits a P/S ratio of --, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MSLE increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MSLE in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MSLE currently overvalued or undervalued?

Satellos Bioscience Inc (MSLE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of --. The fair price of Satellos Bioscience Inc (MSLE) is between to according to relative valuation method.

What is Satellos Bioscience Inc (MSLE) fair value?

MSLE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Satellos Bioscience Inc (MSLE) is between to according to relative valuation method.

How does MSLE's valuation metrics compare to the industry average?

The average P/S ratio for MSLE's competitors is 11.96, providing a benchmark for relative valuation. Satellos Bioscience Inc Corp (MSLE) exhibits a P/S ratio of --, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Satellos Bioscience Inc (MSLE) as of May 13 2026?

As of May 13 2026, Satellos Bioscience Inc (MSLE) has a P/B ratio of 5.77. This indicates that the market values MSLE at 5.77 times its book value.

What is the current FCF Yield for Satellos Bioscience Inc (MSLE) as of May 13 2026?

As of May 13 2026, Satellos Bioscience Inc (MSLE) has a FCF Yield of -14.73%. This means that for every dollar of Satellos Bioscience Inc's market capitalization, the company generates -14.73 cents in free cash flow.

What is the current Forward P/E ratio for Satellos Bioscience Inc (MSLE) as of May 13 2026?

As of May 13 2026, Satellos Bioscience Inc (MSLE) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Satellos Bioscience Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Satellos Bioscience Inc (MSLE) as of May 13 2026?

As of May 13 2026, Satellos Bioscience Inc (MSLE) has a Forward P/S ratio of 0.00. This means the market is valuing MSLE at $0.00 for every dollar of expected revenue over the next 12 months.

MSLE Valuation